Skip to main content

Conference Correspondent

Conference Correspondent

Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multicenter Study of 683 US Patients

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Conference Correspondent, Conference Highlights AMCP

Payers’ Perspective: Incorporating Real-World Evidence in Patient Care

Lilly Ostrovsky

Lilly Ostrovsky

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Conference Correspondent, ASH 2016 - Multiple Myeloma

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Conference Correspondent, ASH 2016 - Multiple Myeloma

Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma

Conference Correspondent

Postmarketing Experience with Belimumab in Patients with Lupus in Clinical Practice Settings Confirms the Evidence from Clinical Trials

3
4
5
6
7
8

Page 6 of 8
Results 51 - 60 of 80